Madrigal on track for MAESTRO-NASH topline data in Q4 2022; Q2 cash $211.8M

MADRIGAL PHARMACEUTICALS, INC.

2022-Q2 EPS reported -$7.50

Topline data from Phase 3 MAESTRO-NASH biopsy study expected in Q4 2022; NDA filing planned for H1 2023.
Cash, cash equivalents and marketable securities of $211.8M as of June 30, 2022, down from $270.3M at Dec 31, 2021.
Q2 2022 operating expenses $70.3M (R&D $58.5M, G&A $11.8M) vs $61.7M in Q2 2021.
Expanded market development activities; payer education sessions covering >80% of U.S. branded prescriptions.
Plans to initiate MAESTRO-NASH Outcomes study in ~700 early NASH cirrhosis patients for full approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.